$CMPSCOMPASS Pathways plc

📅 Upcoming

🕒 Recent(90d)

News

• Trump's FDA pick Overton good for psychedelics, new pain meds but bad for vaccines: analysts
  If confirmed by the Senate, Heidi Overton—officially revealed Wednesday as President Donald Trump’s choice for FDA commissioner—is expected to be a boon for developers of psychedelic therapeutics a…
  biospace · 5h ago
• Definium’s LSD asset beats analyst expectations in Phase 3 anxiety readout
  It’s smooth sailing for Definium Therapeutics as the psychedelic biotech charts another win for its LSD candidate, this time in anxiety. The psychedelic previously notched a late-stage victory in d…
  biospace · 7d ago
• Replimune finally wins approval, Q2 earnings wrap up, psychedelics stay in spotlight
  After two rejections, Replimune has made it across the regulatory finish line with its advanced melanoma therapy. Meanwhile, the last of the major pharmas, including Eli Lilly and Novo Nordisk, rep…
  biospace · 7d ago
• All eyes on psychedelic drugmakers as Definium, Compass near major catalysts
  Definium Therapeutics’ closely watched anxiety readout could further validate its single-dose LSD candidate, while Compass Pathways advances a psilocybin program through a rolling FDA filing.
  biospace · 9d ago
• Psychedelics on the cusp of market breakthrough as clinical, policy support grow
  While there are several FDA-approved psychiatric medicines on the market, many patients still struggle to achieve lasting symptom relief. Psychedelics could help fill this gap.
  biospace · 9d ago
• The next treatment-resistant depression paradigm
  In this episode of Denatured, you’ll hear from Hans Eriksson, chief medical officer at FundaMental Pharma and Steve Levine, chief patient officer at Compass Pathways. We explore why treatment-resis…
  biospace · 13d ago
• Lilly’s $3.8B psychedelics bet won’t open the M&A floodgates
  Eli Lilly’s $3.8 billion play for AtaiBeckley has fueled speculation that Big Pharma is ready to embrace psychedelics. But while the acquisition does validate the drug class, analysts say it is unl…
  biospace · 26d ago
• Lilly’s AtaiBeckley buy validates space as Big Pharma takes note of psychedelics
  Eli Lilly’s proposed acquisition of AtaiBeckley is “the clearest strategic validation to date” of psychedelics as an emerging pharmaceutical category, according to H.C. Wainwright. The analyst caut…
  biospace · 1mo ago
• ‘A rising tide scenario’: Why other Big Pharmas could follow Lilly into psychedelics
  After Eli Lilly dived into the psychedelics space with a $2.8 billion upfront acquisition of AtaiBeckley last week, industry experts told Fierce that the deal would give the space added momentum.
  fiercebiotech · 1mo ago
• Lilly to buy AtaiBeckley for $2.8B, further validating psychedelics
  The latest in a prolific streak of buyouts by Lilly is the strongest sign yet that large pharmaceutical companies may finally be embracing a long-dismissed field of research.
  biopharma_dive · 1mo ago